Methods for treating pulmonary non-tuberculous mycobacterial infections
Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.
1. A method for treating a Mycobacterium avium complex (MAC) lung infection associated with cavitary lesions in a patient previously unresponsive to MAC therapy, comprising:
administering to the lungs of the patient a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, encapsulated in a plurality of liposomes, wherein the lipid component of the plurality of liposomes consists of an electrically neutral phospholipid and cholesterol,
wherein administering to the lungs of the patient comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and
administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient once daily in a single dosing session, for an administration period of at least 6 months,
orally administering to the patient a macrolide antibiotic, ethambutol and a rifamycin compound during the administration period; and
intravenously administering to the patient an aminoglycoside selected from the group consisting of amikacin and streptomycin during the administration period;
wherein the treating comprises achieving a negative MAC sputum culture in the patient.
2. The method of claim 1 , wherein the patient is previously unresponsive to an American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) MAC guideline-based therapy (GBT).
3. The method of claim 2 , wherein the patient is previously unresponsive to the GBT for at least 6 months.
4. The method of claim 1 , wherein the aminoglycoside is amikacin.
5. The method of claim 1 , wherein the macrolide antibiotic is azithromycin, clarithromycin, erythromycin, carbomycin A, josamycin, kitamycin, midecamycin, oleandomycin, solithromycin, spiramycin, troleandomycin, tylosin, roxithromycin, or a combination thereof.
6. The method of claim 5 , wherein the macrolide antibiotic is clarithromycin.
7. The method of claim 5 , wherein the macrolide antibiotic is azithromycin.
8. The method of claim 1 , wherein the rifamycin compound is rifampin.
9. The method of claim 1 , wherein the rifamycin compound is rifabutin.
10. The method of claim 1 , wherein the pharmaceutical composition comprises from about 500 mg to about 650 mg amikacin, or pharmaceutically acceptable salt thereof, encapsulated in the plurality of liposomes.
11. The method of claim 1 , wherein the amikacin or pharmaceutically acceptable salt thereof is amikacin sulfate.
12. The method of claim 1 , wherein the plurality of liposomes comprises unilamellar vesicles, multilamellar vesicles, or a mixture thereof.
13. The method of claim 1 , wherein the electrically neutral phospholipid is an electrically neutral phosphatidylcholine.
14. The method of claim 13 , wherein the electrically neutral phosphatidylcholine is dipalmitoylphosphatidylcholine (DPPC).
15. The method of claim 14 , wherein the pharmaceutical composition comprises about 70 mg/mL amikacin sulfate; about 30 to about 35 mg/mL DPPC; and about 15 to about 17 mg/mL cholesterol.
16. The method of claim 15 , wherein the pharmaceutical composition further comprises about 1.5% NaCl.
17. The method of claim 15 , wherein the pharmaceutical composition has a pH of about 6.5.
18. The method of claim 1 , wherein during the single dosing session, the aerosolized pharmaceutical composition is administered in less than about 15 minutes.
19. The method of claim 1 , wherein during the single dosing session, the aerosolized pharmaceutical composition is administered in about 10 minutes to about 14 minutes.
20. The method of claim 1 , wherein the treating comprises achieving MAC sputum culture conversion in the patient, wherein the MAC sputum culture conversion is defined as three consecutive negative MAC sputum cultures.